Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $144.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 9.62% year-over-year to $144.4 million, compared with a TTM value of $144.4 million through Sep 2025, down 9.62%, and an annual FY2024 reading of $162.7 million, down 26.0% over the prior year.
  • Total Non-Current Liabilities was $144.4 million for Q3 2025 at Bicycle Therapeutics, down from $162.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $229.7 million in Q2 2023 and bottomed at $78.9 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $152.7 million, with a median of $144.4 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities soared 106.49% in 2021, then decreased 26.84% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $130.3 million in 2021, then grew by 4.41% to $136.0 million in 2022, then soared by 61.65% to $219.8 million in 2023, then dropped by 26.0% to $162.7 million in 2024, then decreased by 11.25% to $144.4 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BCYC at $144.4 million in Q3 2025, $162.1 million in Q2 2025, and $142.4 million in Q1 2025.